Zeitschrift fur Epileptologie is a vital resource in the field of neurology and pediatric healthcare, published by Springer Heidelberg. With its ISSN 1617-6782 and E-ISSN 1610-0646, the journal focuses on the latest research and clinical practices pertaining to epilepsy, catering to an audience that includes researchers, clinicians, and students. Although it currently holds a Q4 ranking in both Neurology (clinical) and Pediatrics categories, the journal's commitment to disseminating key findings and enhancing understanding in these fields positions it as an important contributor to ongoing discussions around epilepsy management and child health. The journal has published continuously from 2005 to 2022, offering both traditional and open-access viewing options that increase its accessibility to a global audience. By maintaining an emphasis on high-quality research, Zeitschrift fur Epileptologie strives to improve patient care and embrace innovations in treatment methodologies.

Annals of Indian Academy of Neurology is a premier open access journal dedicated to advancing the field of Neurology, serving as a vital resource for researchers, healthcare professionals, and students since its inception in 2006. Published by the esteemed Wolters Kluwer Medknow Publications, this journal has established itself within the academic community, boasting a Q3 quartile ranking in clinical neurology according to the 2023 category quartiles and a Scopus rank placing it in the 35th percentile among 400 comparable journals. With a focus on clinical advancements and research innovations in neurology, the journal aims to disseminate high-quality and impactful studies that address the complex challenges faced in the neurological landscape, particularly within the Indian context. The open access model ensures that the latest research is readily accessible to a global audience, thereby promoting collaboration and knowledge sharing within the neurosciences.

REVUE NEUROLOGIQUE, published by MASSON EDITEUR, is a prestigious academic journal that plays an essential role in the field of neurology. With a rich history spanning from 1946 to the present, this journal focuses on both foundational and clinical aspects of neurology, underscoring its significance within the medical community. Holding an impressive Q2 ranking in both general and clinical neurology categories as of 2023, REVUE NEUROLOGIQUE is recognized for its contribution to advancing neurological science, as evidenced by its Scopus rankings, with a notable position in the 62nd percentile for clinical neurology. The journal fosters an environment for rigorous research and is instrumental for professionals and scholars aiming to stay abreast of the latest developments in neurological disorders and treatments. Although it is not an open-access publication, it offers a wealth of vital research through its issues, appealing to those engaged in both clinical practice and academic research in neurology.

Tumori Journal is a distinguished publication in the field of oncology, dedicated to advancing the understanding and treatment of cancer since its inception in 1946. Published by SAGE Publications Ltd, this Italian journal serves as a pivotal platform for researchers, clinicians, and academicians to disseminate cutting-edge findings in cancer research and related areas of medicine. With an impressive record of contributions spanning multiple decades, Tumori Journal aims to foster collaboration and dialogue among professionals in the oncology community. Although classified in the Q4 category for Cancer Research and the Q3 category for both Medicine (miscellaneous) and Oncology as of 2023, the journal continues to draw interest with its rigorous peer-review process and commitment to quality. Researchers are encouraged to explore innovative methodologies and share impactful clinical insights through the journal, which also ranks within the top tiers of Scopus metrics for oncology and cancer research domains. With a growing emphasis on accessible research, Tumori Journal remains an essential resource in the continuous fight against cancer.

EPILEPSY RESEARCH is a distinguished journal published by Elsevier, focusing on the dynamic field of neurology with a specific emphasis on epilepsy and related neurological disorders. Since its inception in 1987, the journal has become a vital platform for disseminating cutting-edge research, contributing significantly to the understanding of epileptic conditions and their clinical implications. With an impactful presence in the academic community, EPILEPSY RESEARCH currently holds a 2023 Q2 ranking in both the Neurology and Clinical Neurology categories, reflecting its commitment to high-quality, peer-reviewed content. The journal is indexed in SCOPUS, Ranking #173/400 in Clinical Neurology and #91/192 in Neuroscience, ensuring widespread visibility and academic engagement. Although not an open access publication, it provides critical insights, findings, and reviews that are essential for researchers, clinicians, and students alike, fostering advancements in epilepsy research and treatment. For any inquiries, the journal is based at Radarweg 29, 1043 NX Amsterdam, Netherlands.

Oncology Research and Treatment, published by KARGER, is a highly regarded academic journal dedicated to advancing the field of oncology through rigorous research and clinical insights. With a history spanning from 1978 to 1997 and continuing from 2013 to 2024, this journal provides a vital platform for researchers and professionals in cancer research, hematology, and related disciplines. Though currently listed in the Q3 tier of 2023 for Cancer Research, Hematology, and Oncology, its growing readership and open access policy enhance its visibility and impact within the scientific community. Based in Switzerland, the journal features diverse access options, reflecting the global importance of oncology research. With a focus on innovative treatments and the latest methodologies, Oncology Research and Treatment plays a crucial role in fostering collaboration and dialogue among researchers, professionals, and students alike, helping to shape the future of cancer care and management.

The Cochrane Database of Systematic Reviews is a premier journal published by WILEY, focusing on the critical appraisal and synthesis of high-quality research in health care. With its dedication to evidence-based practice, this journal serves as a cornerstone for researchers, healthcare professionals, and students alike, offering pivotal insights through rigorous systematic reviews. Although it is not an open-access publication, its influence in guiding clinical decision-making and policy formulation is profound, underscored by its contributions to the advancement of healthcare knowledge. Based in the United States at 111 River St, Hoboken, NJ, the Cochrane Database has established itself as essential reading for those seeking to stay at the forefront of systematic reviews and meta-analyses in the medical field, ensuring that users are well-equipped with the evidence necessary for informed practice.

Therapeutic Advances in Neurological Disorders, published by SAGE Publications Ltd, is a leading open access journal dedicated to the advancement of knowledge in the field of neurology. Since its inception in 2008, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for the dissemination of high-quality research that improves the understanding and treatment of neurological disorders. With a commendable impact factor and ranked Q1 in multiple categories, including Neurology and Pharmacology for 2023, it exemplifies excellence in scholarly contributions. The journal's Scope encompasses a wide array of topics, providing insights that are pivotal for clinical practice and pharmacological development. Additionally, with its commitment to open access since 2017, Therapeutic Advances in Neurological Disorders ensures that its research reaches a global audience, fostering collaboration and innovation in neurological science.

JAMA Neurology is a leading peer-reviewed journal published by the American Medical Association, focused on advancing the understanding and treatment of neurological disorders. With an impressive impact factor and ranked in the 99th percentile among clinical neurology journals, this publication is recognized as Q1 in its category for 2023, highlighting its significance in the field. Since its inception, the journal has provided a platform for high-quality research, clinical trials, and reviews that inform both clinicians and researchers. Operating from its headquarters in Chicago, Illinois, JAMA Neurology offers rich insights into the latest advancements in neurology, featuring articles that span a wide range of topics including neurodegenerative diseases, stroke, epilepsy, and neurocritical care. Researchers and professionals are encouraged to access the journal’s content freely, as it employs open access options to promote the dissemination of critical knowledge. As a critical resource in the field of neurology, JAMA Neurology is essential for anyone involved in this dynamic and rapidly evolving specialty.

Movement Disorders Clinical Practice, published by WILEY, is an essential peer-reviewed journal dedicated to advancing the understanding and treatment of movement disorders from a clinical perspective. With an ISSN of 2330-1619, this journal serves as a vital resource for researchers, clinicians, and students engaged in neurology and clinical neuroscience. Since its inception in 2014, the journal has established itself within the medical community, currently positioned in the Q2 category for both Neurology and Neurology (Clinical), reflecting its influence and reputation. Although it does not offer open access, the journal is integral for disseminating high-quality research and clinical insights, thereby contributing significantly to improved patient care and outcomes in the field of movement disorders. Based in Hoboken, NJ, it continues to attract contributions from leading experts and aims to foster a deeper understanding and dialogue surrounding contemporary challenges and advancements in movement disorder treatment.